Fabry cardiomyopathy

• Published in: Journal of Cardiovascular Ultrasound 2013-03, Vol.21 (1), p.26-29
• Main Authors: Yoon, Jae Yong, Song, Joon Hyuk, Cheon, Sang Soo, Cho, Hyun Jun, Bae, Myung Hwan, Lee, Jang Hoon, Yang, Dong Heon, Park, Hun Sik, Cho, Yongkeun, Chae, Shung Chull
• Format: Article
• Language: English
• Subjects: Case Report
• ISSN: 1975-4612; 2005-9655
• DOI: 10.4250/jcu.2013.21.1.26

Fabry disease is a progressive X-linked disorder of glycosphingolipid metabolism caused by a deficiency of the α-galactosidase lysosomal enzyme. The partial or complete deficiency of the lysosomal enzyme leads to an accumulation of neutral glycosphingolipids in the vascular endothelium and visceral tissues throughout the body. In the heart, glycosphingolipids deposition causes progressive left ventricular hypertrophy (LVH). We report a case of Fabry disease which was suspected based upon two-dimensional echocardiographic finding of LVH. A 44-year-old man was admitted to evaluation of aggravated exertional dyspnea of two weeks duration. He had been diagnosed with end-stage renal disease of unknown etiology at age 41 followed by renal transplantation that year. He had been treated with oral immunosuppressive agents. On hospital day two, transthoracic echocardiography revealed concentric LVH. Left ventricular systolic function was preserved but diastolic dysfunction was present. Fabry disease was confirmed by demonstration of a low plasma α-galactosidase A (α-Gal A) activity. Analysis of genomic DNA showed α-Gal A gene mutation. The patient was diagnosed with Fabry disease.